FRANKFURT (Reuters) -Swiss drugmaker Roche on Thursday lifted its full-year guidance after reporting nine-month sales that were better than expected.
In a statement, the group said it expects a currency-adjusted increase in 2025 sales in the "mid single digit" percentage range.
It also projected a gain in adjusted earnings per share in the "high single to low double digit" percentage range.